{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:45:07Z","timestamp":1774014307875,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The German Hodgkin Study Group (GHSG) HD17 trial established the omission of radiotherapy (RT) for patients with early-stage unfavorable Hodgkin lymphoma being PET-negative after 2 cycles of BEACOPP escalated plus 2 cycles of ABVD. This patient group reveals heterogeneity in characteristics and disease extent which prompted us to perform a decisive dosimetric analysis according to GHSG risk factors. This may help to tailor RT individually balancing risks and benefits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For quality assurance, RT-plans were requested from the treating facilities (n= 141) and analyzed centrally. Dose-volume histograms were scanned either paper-based or digitally to obtain doses to mediastinal organs. These were registered and compared according to GHSG risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, RT plans of 176 patients were requested, 139 of which had dosimetric information on target volumes within the mediastinum. Most of these patients were stage II (92.8%), had no B-symptoms (79.1%) and were aged &amp;lt; 50 years (89.9%). Risk factors were present in 8.6% (extranodal involvement), 31.7% (bulky disease), 46.0% (elevated erythrocyte sedimentation rate) and 64.0% (three involved areas), respectively. The presence of bulky disease significantly affected the mean RT doses to the heart (p=0.005) and to the left lung (median: 11.3 Gy vs. 9.9 Gy; p=0.042) as well as V5 of the right and left lung, respectively (median right lung: 67.4% vs. 51.0%; p=0.011; median left lung: 65.9% vs. 54.2%; p=0.008). Significant differences in similar organs at risk parameters could be found between the sub-cohorts with the presence or absence of extranodal involvement, respectively. In contrast, an elevated erythrocyte sedimentation rate did not deteriorate dosimetry significantly. No association of any risk factor with radiation doses to the female breast was found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pre-chemotherapy risk factors may help to predict potential RT exposure to normal organs and to critically review treatment indication. Individualized risk-benefit evaluations for patients with HL in early-stage unfavorable disease are mandatory.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1183906","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T06:04:01Z","timestamp":1683266641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma\u2013 a risk stratified analysis of the GHSG HD17 trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Michael","family":"Oertel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Hering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Baues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Engenhart-Cabillic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable hodgkin\u2019s lymphoma: final analysis of the German Hodgkin study group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijrobp.2017.09.048","article-title":"Reduced mortality risk in the recent era in early-stage Hodgkin lymphoma patients treated with radiation therapy with or without chemotherapy","volume":"100","author":"Patel","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-term cause-specific mortality in Hodgkin lymphoma patients","volume":"113","author":"de Vries","year":"2021","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","volume-title":"(Deutsche krebsgesellschaft, deutsche krebshilfe, AWMF): diagnostik, therapie und nachsorge des Hodgkin lymphoms bei erwachsenen patienten","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-022-01171-2","article-title":"Therapiealgorithmus f\u00fcr patienten mit Hodgkin-lymphom","volume":"28","author":"Engert","year":"2022","journal-title":"Onkologie"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","article-title":"Radiation therapy in the German hodgkin study group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-008-1882-7","article-title":"Involved-node radiotherapy in early-stage hodgkin\u2019s lymphoma: definition and guidelines of the German Hodgkin study group (GHSG)","volume":"184","author":"Eich","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3238\/arztebl.m2021.0024","article-title":"Late sequelae of radiotherapy\u2014the effect of technical and conceptual innovations in radiation oncology","volume":"118","author":"Hoeller","year":"2021","journal-title":"Deutsches \u00c4rzteblatt Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00408","article-title":"Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography\u2013directed therapy for early-stage Hodgkin lymphoma","volume":"39","author":"Cutter","year":"2021","journal-title":"JCO"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00066-020-01682-0","article-title":"Impact of radiation techniques on lung toxicity in patients with mediastinal hodgkin\u2019s lymphoma","volume":"197","author":"Pepper","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.05.035","article-title":"Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients","volume":"81","author":"Weber","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23081","article-title":"Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma","volume":"110","author":"Hodgson","year":"2007","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831215)52:12<2223::aid-cncr2820521209>3.0.co;2-d","article-title":"Patterns of care study: hodgkin\u2019s disease relapse rates and adequacy of portals","volume":"52","author":"Kinzie","year":"1983","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.035","article-title":"A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of hodgkin\u2019s lymphoma\u2013analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin study group (GHSG)","volume":"69","author":"Eich","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.12.002","article-title":"Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) hodgkin\u2019s lymphoma: an analysis of the German Hodgkin study group","volume":"71","author":"Eich","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000092701.47861.81","article-title":"The HD12 panel of the German Hodgkin lymphoma study group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients\u2019 imaging","volume":"27","author":"Eich","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-016-1036-2","article-title":"Quality control of involved field radiotherapy in the HD 13 and HD 14 trials: report of the radiotherapy panel of the German Hodgkin study group (GHSG)","volume":"193","author":"Kriz","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2905","article-title":"Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage hodgkin\u2019s disease: long-term results of a randomized trial of radiotherapy alone","volume":"19","author":"D\u00fchmke","year":"2001","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijrobp.2015.01.048","article-title":"Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin study group","volume":"92","author":"Kriz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.08.033","article-title":"Centralized radiation oncologic review of cross-sectional imaging of hodgkin\u2019s disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin study group","volume":"58","author":"Eich","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)01565-7","article-title":"Initiation of a teleradiotherapeutic network for patients in German lymphoma studies","volume":"58","author":"Eich","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin lymphoma - data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"van Heek","year":"2022","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin study group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2022","journal-title":"J Clin Oncol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1183906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:03:24Z","timestamp":1683795804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1183906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":38,"alternative-id":["10.3389\/fonc.2023.1183906"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1183906","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1183906"}}